A proteomic profiling of laser-microdissected lung adenocarcinoma cells of early lepidic-types

Yasufumi Kato1, Haruhiko Nakamura2, Hiromasa Tojo3, Masaharu Nomura1, Toshitaka Nagao4, Takeshi Kawamura5, Tatsuhiko Kodama5, Tatsuo Ohira1, Norihiko Ikeda1, Thomas Fehniger6,7, György Marko-Varga1,6,7, Toshihide Nishimura1,6*, and Harubumi Kato1,8

Abstract

Background: In the new pathologic classification of lung adenocarcinoma proposed by IASLC/ATS/ERS in 2011, lepidic type adenocarcinomas are constituted by three subtypes; adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA) and lepidic predominant invasive adenocarcinoma (LPIA). Although these subtypes are speculated to show sequential progression from preinvasive lesion to invasive lung cancer, changes of protein expressions during these processes have not been fully studied yet. This study aims to glimpse a proteomic view of the early lepidic type lung adenocarcinomas.

Methods: A total of nine formalin-fixed and paraffin-embedded (FFPE) lepidic type lung adenocarcinoma tissues were selected from our archives, three tissues each in AIS, MIA and LPIA. The tumor and peripheral non-tumor cells in these FFPE tissues were collected with laser microdissection (LMD). Using liquid chromatography-tandem mass spectrometry (MS/MS), protein compositions were compared with respect to the peptide separation profiles among tumors collected from three types of tissues, AIS, MIA and LPIA. Proteins identified were semi-quantified by spectral counting-based or identification-based approach, and statistical evaluation was performed by pairwise G-tests.

Results: A total of 840 proteins were identified. Spectral counting-based semi-quantitative comparisons of all identified proteins through AIS to LPIA have revealed that the protein expression profile of LPIA was significantly differentiated from other subtypes. 70 proteins including HPX, CTTN, CDH1, EGFR, MUC1 were found as LPIA-type marker candidates, 15 protein candidates for MIA-type marker included CRABP2, LMO7, and RNPEP, and 26 protein candidates for AIS-type marker included LTA4H and SOD2. The STRING gene set enrichment resulted from the protein-protein interaction (PPI) network analysis suggested that AIS was rather associated with pathways of focal adhesion, adherens junction, tight junction, that MIA had a strong association predominantly with pathways of proteoglycans in cancer and with PI3K-Akt. In contrast, LPIA was associated broadly with numerous tumor-progression pathways including ErbB, Ras, Rap1 and HIF-1 signalings.

Conclusions: The proteomic profiles obtained in this study demonstrated the technical feasibility to elucidate protein candidates differentially expressed in FFPE tissues of LPIA. Our results may provide candidates of disease-oriented proteins which may be related to mechanisms of the early-stage progression of lung adenocarcinoma.

Keywords: Lung cancer; Adenocarcinoma; Lepidic type adenocarcinoma; Adenocarcinoma in situ; Minimally invasive adenocarcinoma; Comparative proteomics; Formalin-fixed and paraffin-embedded tissue sections; Laser microdissection; Mass spectrometry; Protein-protein interaction
Background

Lung cancer is the leading cause of cancer-related mortality worldwide [1]. In Japan, annual deaths from lung cancer are increasing and currently approach about 70,000 [2], while in the United States with a recent decreasing trend in mortality, more than 160,000 succumb annually [3]. In an increasing trend worldwide, advances in chest high-resolution computed tomography (HRCT) scanning technology have enabled the localization of small adenocarcinoma nodules [4] at an earlier and potentially more curable stage of development than previously possible [5]. There are 90 million current and ex-smokers in the United States who are at increased risk of lung cancer. The published data from the National Lung Screening Trial (NLST) suggest that yearly screening with low-dose thoracic CT scan in heavy smokers can reduce lung cancer mortality by 20 % and all-cause mortality by 7-% [6].

In 2011, the new pathologic classification of lung adenocarcinoma was proposed by the International Association for the Study of Lung Cancer (IASLC), the American Thoracic Society (ATS) and the European Respiratory Society (ERS) [7]. In the new classification, the concept of adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA) were newly introduced and the term bronchioloalveolar carcinoma (BAC) was abolished. Additionally, invasive adenocarcinomas were categorized into 6 subtypes, lepidic, acinar, papillary, micropapillary, solid, and variants, according to the predominant histologic pattern. Both AIS and MIA were defined as tumors ≤ 3 cm in size. AIS is a preinvasive lesion showing pure lepidic growth without invasion. MIA is also lepidic predominant tumor but with ≤ 5 mm invasion. LPIA is an invasive adenocarcinoma showing former nonmucinous BAC pattern with > 5 mm invasion. These 3 lepidic type adenocarcinomas are speculated to show step-wise progression from AIS, MIA, to LPIA. After complete resection of AIS or MIA, usually 100 % of recurrence-free 5-year survival can be obtained [7], while some recurrent cases are found after resection of LPIA [8–10]. Since postoperative prognoses between the AIS plus MIA group and LPIA are different, differential protein expressions associated with invasiveness of cancer cells in each subtype should play important roles to determine local recurrences and survivals. However, precise proteomic analyses using individual cells in these early adenocarcinomas have not yet been performed. To the best of our knowledge, this is the first report performing proteomic analysis using micro-dissected early phase lung adenocarcinoma cells.

Recent advancements in shotgun sequencing and quantitative mass spectrometry for protein analyses could make proteomics amenable to clinical biomarker discovery [11, 12]. Laser microdissection (LMD) made it possible to collect target cells from a variety of formalin fixed paraffin embedded (FFPE) cancer tissues. This study attempts to capture a proteomic view of LPIA in comparison with other early stage lung adenocarcinomas by utilizing a label-free identification-based (or spectral counting-based) semi-quantitative shotgun proteomics approach following LMD [13–19].

Results and discussion

Group comparisons by Rsc and G-statistics

We used Abacus [20] to select high-scoring proteins using the thresholds of PeptideProphet probability > 0.99 and ProteinProphet probability > 0.9 as described in “MATERIALS and METHODS”, resulting in identifying a total of 840 proteins and obtaining their values of raw fold change in log2 (Rsc). For G-test (p < 0.05) [21], the raw SpCs of all patients in each group were pooled, thereby improving the performance of G-test and decreasing false positive rates significantly [15, 22]. Next, the values of Rsc that is a measure of fold changes for protein expression levels were calculated as described in “Materials and Methods” using the spectral counts of these proteins.

The full lists of 840 proteins identified were provided as Additional file 1: Table S3. Proteins in LPIA, MIA and AIS identified under SpCtotal > 2 for a protein were 789, 607, and 544, respectively, and were subjected to gene ontology (GO) analysis by using PANTHER Ver. 10.0 (http://www.pantherdb.org/). Results of (A) biological processes and (B) protein classes are shown in Fig. 1.

A marker candidate for the LPIA-type was chosen under the following criterions so that a protein had the pairwise p-value < 0.05 in G-test and Rsc < −1 against MIA and AI, [LPIA] (the relative abundance in spectral count) higher than [MIA] and [AIS], and total spectral counts throughout the disease states > 5. Table 1 summarizes 70 protein candidates thus obtained for LPIA from total 840 proteins identified, which are listed in increasing order of the Rsc (LPIA vs. MIA) values; the negatively larger the Rsc value of a given protein, the greater its expression level in LPIA compared with MIA and AIS. Those included beta-actin-like protein 2 (ACTBL2), tubulin alpha-1C chain (TUBA1C), band 7 protein family protein, HLA class I histocompatibility antigen, A-2 alpha chain (HLA-A), ARPC4-TTLL3 fusion protein, epilakin (EPPK1), synaptogyrin-2 (SYNGR2), hemopexin (HPX), small nuclear ribonucleoprotein G-like protein (SNRPF), src substrate cortactin (CTTN), cadherin-1 (CDH1) (known as E-cadherin), epidermal growth factor receptor (EGFR), mucin-1 (MUC1), and promyelocytic leukemia protein (PML). The high expression of beta-actin-like protein 2 (ACTBL2) and tubulin alpha-1C chain (TUBA1C) might be related to active actin polymerization associated with invasiveness of LPIA.

Src substrate cortactin (CTTN), epidermal growth factor receptor (EGFR) and mucin-1 (MUC1) expressed in
LPIA might reflect its invasiveness with aggressive proliferation. Invasive carcinoma cells degrade and invade through the extracellular matrix (ECM) by invadopodia, where an EGFR–Src–Arg–cortactin pathway is considered to mediate functional maturation of invadopodia [23–25]. Overexpression of cortactin protein (CTTN) has been currently considered to be an important biomarker for invasive cancers because of its frequent link to various invasive cancers, including melanoma, colorectal, and glioblastoma [25].

Proteins expressed increasing along the disease stages from AIS to LPIA, which might be considered to be disease progression-related, included were alpha-enolase (ENO1), plectin (PLEC), major vault protein (MVP), heterogeneous nuclear ribonucleoprotein M (HNRNPM), 14-3-3 protein sigma (SFN), lysophosphatidylcholine acyltransferase 1 (LPCAT1), anterior gradient protein 2 homolog (AGR2), phospholipase D3 (PLD3), hypoxia up-regulated protein 1 (HYOU1), fatty acid synthase (FASN), programmed cell death protein 6 (PDCD6), and ethylmalonyl-CoA decarboxylase (ECHDC1). Among proteins expressed characteristically in the AIS and MIA disease stages, leukotriene A-4 hydrolase (LTA4H) in AIS and cellular retinoic acid-binding protein 2 (CRABP2) in MIA, respectively, were representative. Proteins significant to AIS and MIA are provided in Additional file 1: Table S1 and S2. Enhanced AGR2 expression has been observed in most human adenocarcinomas,
Table 1  Seventy protein candidates characterizing LPIA listed in increasing order of the $Rsc$ (LPIA vs. MIA) values; the negatively larger the $Rsc$ value of a given protein, the greater its expression level in LPIA compared with MIA and AIS.

| No | Accession/Number/Code | Gene ID | Description | Protein length (AA) | Spectral counts (SpCs) | Relative % throughout stages | Fold change in log2 ($Rsc_{pN}$) | $p$-value in G-test |
|----|-----------------------|---------|-------------|---------------------|------------------------|-----------------------------|-------------------------------|------------------|
| 1  | HIP000323690          | Band 7 protein family protein | 2858 | 77 | 0 | 77 | 100.0 | 0.0 | 0.0 | -5.816 | -5.758 | -4.482 | 2.33E-22 | 5.80E-22 | 1.67E-13 |
| 2  | P01892                | HLA-A | HLA class I histocompatibility antigen, A-2 alpha chain | 365 | 34 | 0 | 34 | 100.0 | 0.0 | 0.0 | -4.663 | -4.605 | -3.329 | 3.75E-10 | 5.59E-10 | 2.94E-06 |
| 3  | Q15233                | NONO   | Non-POU domain-containing octamer-binding protein | 471 | 32 | 0 | 6 | 84.2 | 0.0 | 15.8 | -4.579 | -1.984 | -3.244 | 1.38E-09 | 9.10E-05 | 6.39E-06 |
| 4  | P31948                | STIP1  | Stress-induced-phosphoprotein 1 | 543 | 27 | 0 | 5 | 84.4 | 0.0 | 15.6 | -4.344 | -1.963 | -3.009 | 3.75E-10 | 5.59E-10 | 2.94E-06 |
| 5  | P10253                | GAA    | Lysosomal alpha-glucosidase | 952 | 26 | 0 | 26 | 100.0 | 0.0 | 0.0 | -4.292 | -4.233 | -2.957 | 6.99E-08 | 9.48E-08 | 6.57E-05 |
| 6  | Q07065                | CKAP4  | Cytoskeleton-associated protein 4 | 602 | 24 | 0 | 5 | 82.8 | 0.0 | 17.2 | -4.181 | -1.801 | -2.847 | 2.58E-07 | 1.43E-03 | 1.43E-04 |
| 7  | P17858                | PFKL   | 6-phosphofructokinase, liver type | 780 | 22 | 0 | 24 | 91.7 | 0.0 | 8.3 | -4.062 | -2.625 | -2.727 | 9.55E-07 | 9.43E-05 | 3.11E-04 |
| 8  | Q07960                | ARHGAP1| Rho GTPase-activating protein 1 | 439 | 20 | 0 | 20 | 100.0 | 0.0 | 0.0 | -3.932 | -3.874 | -2.598 | 3.33E-06 | 4.47E-06 | 6.77E-04 |
| 9  | P06865                | HEXA   | Beta-hexosaminidase subunit alpha | 529 | 19 | 0 | 19 | 100.0 | 0.0 | 0.0 | -3.863 | -3.804 | -2.528 | 6.86E-06 | 8.46E-06 | 9.99E-04 |
| 10 | P35007                | SLC25A1| Tricarboxylate transport protein, mitochondrial | 311 | 18 | 0 | 18 | 100.0 | 0.0 | 0.0 | -3.790 | -3.731 | -2.455 | 1.31E-05 | 1.61E-05 | 1.47E-03 |
| 11 | P36871                | PGM1   | Phosphoglucomutase-1 | 562 | 18 | 0 | 18 | 100.0 | 0.0 | 0.0 | -3.790 | -3.731 | -2.455 | 1.31E-05 | 1.61E-05 | 1.47E-03 |
| 12 | A0A0A6YYG9            | ARPC4-TTLL3 fusion protein | 625 | 18 | 0 | 18 | 100.0 | 0.0 | 0.0 | -3.790 | -3.731 | -2.455 | 1.31E-05 | 1.61E-05 | 1.47E-03 |
| 13 | Q96HE7                | ERO1L  | ERO1-like protein alpha | 468 | 16 | 0 | 16 | 100.0 | 0.0 | 0.0 | -3.631 | -3.573 | -2.296 | 4.84E-05 | 5.84E-05 | 3.21E-03 |
| 14 | Q02218                | OGDH   | 2-oxoglutarate dehydrogenase, mitochondrial | 1023 | 16 | 0 | 17 | 94.1 | 0.0 | 5.9 | -3.631 | -2.725 | -2.296 | 4.84E-05 | 5.45E-04 | 3.21E-03 |
| 15 | PS8107                | EPPK1  | Epilakin | 5090 | 15 | 0 | 15 | 100.0 | 0.0 | 0.0 | -3.545 | -3.487 | -2.210 | 9.32E-05 | 1.11E-04 | 4.75E-03 |
| 16 | P49588                | AARS   | Alanine–tRNA ligase, cytoplasmic | 968 | 15 | 0 | 15 | 100.0 | 0.0 | 0.0 | -3.545 | -3.487 | -2.210 | 9.32E-05 | 1.11E-04 | 4.75E-03 |
| 17 | P16615                | ATP2A2 | Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 | 997 | 15 | 0 | 15 | 100.0 | 0.0 | 0.0 | -3.545 | -3.487 | -2.210 | 9.32E-05 | 1.11E-04 | 4.75E-03 |
| 18 | P62873                | GNBI   | Guanine nucleotide-binding protein G(II/G(III)/GT) subunit beta-1 | 340 | 14 | 0 | 14 | 100.0 | 0.0 | 0.0 | -3.453 | -3.395 | -2.119 | 1.80E-04 | 2.11E-04 | 7.01E-03 |
| 19 | O43760                | SYNGR2 | Synaptogyrin-2 | 224 | 14 | 0 | 14 | 100.0 | 0.0 | 0.0 | -3.453 | -3.395 | -2.119 | 1.80E-04 | 2.11E-04 | 7.01E-03 |
| 20 | O60701                | UGDH   | UDP-glucose 6-dehydrogenase | 494 | 12 | 0 | 12 | 100.0 | 0.0 | 0.0 | -3.250 | -3.192 | -1.916 | 6.66E-04 | 7.66E-04 | 1.53E-02 |
| 21 | Q572N8                | ATAD3C | ATPase family AAA domain-containing protein 3C | 411 | 11 | 0 | 11 | 100.0 | 0.0 | 0.0 | -3.137 | -3.079 | -1.802 | 1.28E-03 | 1.46E-03 | 2.27E-02 |
| 22 | P46782                | RP55   | 40S ribosomal protein S5 | 204 | 11 | 0 | 11 | 100.0 | 0.0 | 0.0 | -3.137 | -3.079 | -1.802 | 1.28E-03 | 1.46E-03 | 2.27E-02 |
| 23 | Q8NB17                | SUMF2  | Sulfatase-modifying factor 2 | 301 | 11 | 0 | 13 | 84.6 | 0.0 | 15.4 | -3.137 | -1.700 | -1.802 | 1.28E-03 | 3.46E-02 | 2.27E-02 |
| 24 | Q96AE4                | FUBP1  | Far upstream element-binding protein 1 | 644 | 10 | 0 | 10 | 100.0 | 0.0 | 0.0 | -3.014 | -2.956 | -1.679 | 2.48E-03 | 2.78E-03 | 3.36E-02 |
Table 1 Seventy protein candidates characterizing LPIA listed in increasing order of the Rsc (LPIA vs. MIA) values; the negatively larger the Rsc value of a given protein, the greater its expression level in LPIA compared with MIA and AIS (Continued)

| No. | Accession | Gene Symbol | Description | RPIA | RPIA | RPIA | RPIA | RPIA | RPIA | RPIA |
|-----|-----------|-------------|-------------|------|------|------|------|------|------|------|
| 25  | P46783    | RPS10       | 40S ribosomal protein S10 | 165  | 10   | 0    | 0    | 10   | 100.0| 0.0  | 0.0  |
| 26  | P17516    | AKR1C4      | Aldo-keto reductase family 1 member C4 | 323  | 10   | 0    | 0    | 10   | 100.0| 0.0  | 0.0  |
| 27  | P15531    | NME1        | Nucleoside diphosphate kinase A | 152  | 10   | 0    | 0    | 10   | 100.0| 0.0  | 0.0  |
| 28  | P15428    | HPGD        | 15-hydroxyprostaglandin dehydrogenase [NAD(+)] | 266  | 10   | 0    | 0    | 10   | 100.0| 0.0  | 0.0  |
| 29  | O43776    | NARS        | Asparagine–tRNA ligase, cytoplasmic | 548  | 10   | 0    | 0    | 10   | 100.0| 0.0  | 0.0  |
| 30  | P68036    | UBE2L3      | Ubiquitin-conjugating enzyme E2 L3 | 154  | 9    | 0    | 0    | 9    | 100.0| 0.0  | 0.0  |
| 31  | P15856    | MTHFD1      | C-1-tetrahydrofolate synthase, cytoplasmic | 935  | 9    | 0    | 0    | 9    | 100.0| 0.0  | 0.0  |
| 32  | P11586    | MTHFD1      | C-1-tetrahydrofolate synthase, cytoplasmic | 935  | 9    | 0    | 0    | 9    | 100.0| 0.0  | 0.0  |
| 33  | P02790    | HPX         | Hemopexin | 462  | 9    | 0    | 0    | 9    | 100.0| 0.0  | 0.0  |
| 34  | Q9Y3U8    | RPL36       | 60S ribosomal protein L36 | 105  | 8    | 0    | 0    | 8    | 100.0| 0.0  | 0.0  |
| 35  | P62491    | RAB11A      | Ras-related protein Rab-11A | 216  | 8    | 0    | 0    | 8    | 100.0| 0.0  | 0.0  |
| 36  | P56192    | MARS        | Methionine–tRNA ligase, cytoplasmic | 900  | 8    | 0    | 0    | 8    | 100.0| 0.0  | 0.0  |
| 37  | P12830    | CDH1        | Cadherin-1 | 882  | 8    | 0    | 0    | 8    | 100.0| 0.0  | 0.0  |
| 38  | P05166    | PCCB        | Propionyl-CoA carboxylase beta chain, mitochondrial | 559  | 8    | 0    | 0    | 8    | 100.0| 0.0  | 0.0  |
| 39  | O75347    | TBCA        | Tubulin-specific chaperone A | 108  | 8    | 0    | 0    | 8    | 100.0| 0.0  | 0.0  |
| 40  | Q043684   | BUB3        | Mitotic checkpoint protein BUB3 | 328  | 8    | 0    | 0    | 8    | 100.0| 0.0  | 0.0  |
| 41  | Q9UM22    | EPDR1       | Mammalian ependymin-related protein 1 | 224  | 7    | 0    | 0    | 7    | 100.0| 0.0  | 0.0  |
| 42  | Q14376    | GALE        | UDP-glucose 4-epimerase | 348  | 7    | 0    | 0    | 7    | 100.0| 0.0  | 0.0  |
| 43  | P48637    | GSS         | Glutathione synthetase | 474  | 7    | 0    | 0    | 7    | 100.0| 0.0  | 0.0  |
| 44  | P47897    | QARS        | Glutamine–tRNA ligase | 775  | 7    | 0    | 0    | 7    | 100.0| 0.0  | 0.0  |
| 45  | P15941    | MUC1        | Mucin-1 | 475  | 7    | 0    | 0    | 7    | 100.0| 0.0  | 0.0  |
| 46  | O60763    | USO1        | General vesicular transport factor p115 | 962  | 7    | 0    | 0    | 7    | 100.0| 0.0  | 0.0  |
| 47  | P46977    | STT3A       | Dolichyl-diphosphoglycerol-synthase–protein glycosyltransferase subunit STT3A | 705  | 12   | 1    | 0    | 13   | 92.3 | 7.7  | 0.0  |
| 48  | O43488    | AKR7A2      | Aflatoxin B1 aldehyde reductase member 2 | 358  | 12   | 1    | 1    | 14   | 85.7 | 7.1  | 7.1  |
| 49  | Q9Y3I0    | C22orf28    | tRNA-splicing ligase RtcB homolog | 505  | 6    | 0    | 0    | 6    | 100.0| 0.0  | 0.0  |
| 50  | P29590    | PML         | Protein PML | 633  | 6    | 0    | 0    | 6    | 100.0| 0.0  | 0.0  |
| #  | Accession  | Name                          | Gene Descriptions                                                                 | Rsc (LPIA vs. MIA) | N1 | N2 | N3 | N4 | N5 | N6 | N7 | N8 | N9 | N10 |
|----|------------|-------------------------------|------------------------------------------------------------------------------------|-------------------|----|----|----|----|----|----|----|----|----|----|----|
| 56 | P14868     | DARS                          | Aspartate–tRNA ligase, cytoplasmic                                                | -2.380            | 6  | 0  | 6  | 100.0 | 0.0 | -2.380 | -2.322 | -1.045 | 3.45E-02 | 3.70E-02 | 1.63E-01 |
| 57 | P00533     | EGFR                          | Epidermal growth factor receptor                                                  | -2.380            | 6  | 0  | 6  | 100.0 | 0.0 | -2.380 | -2.322 | -1.045 | 3.45E-02 | 3.70E-02 | 1.63E-01 |
| 58 | Q02252     | ALDH6A1                       | Methylmalonate-semialdehyde dehydrogenase [acylating], mitochondrial             | -2.372            | 29 | 4  | 9  | 42  | 69.0 | 9.5 | 21.4 | -2.372 | -1.348 | -3.108 | 2.84E-05 | 4.68E-03 | 2.05E-05 |
| 59 | Q99829     | CPNE1                         | Copine-1                                                                           | -2.221            | 26 | 4  | 7  | 37  | 70.3 | 10.8 | 18.9 | -2.221 | -1.510 | -2.957 | 1.38E-04 | 3.51E-03 | 6.57E-05 |
| 60 | Q15363     | TMED2                         | Transmembrane emp24 domain-containing protein 2                                    | -2.166            | 10 | 1  | 0  | 11  | 90.9 | 9.1 | 0.0  | -2.166 | -2.956 | -1.679 | 1.57E-02 | 2.78E-03 | 3.36E-02 |
| 61 | P35221     | CTNNA1                        | Catenin alpha-1                                                                    | -2.072            | 28 | 5  | 10 | 43  | 65.1 | 11.6 | 23.3 | -2.072 | -1.165 | -3.059 | 1.61E-04 | 1.31E-02 | 3.02E-05 |
| 62 | O75340     | PDCD6                         | Programmed cell death protein 6                                                   | -1.953            | 30 | 6  | 3  | 39  | 76.9 | 15.4 | 7.7  | -1.953 | -2.665 | -3.155 | 1.78E-04 | 5.33E-06 | 1.39E-05 |
| 63 | O00764     | PDXK                          | Pyridoxal kinase                                                                   | -1.759            | 11 | 2  | 2  | 15  | 73.3 | 13.3 | 13.3  | -1.759 | -1.700 | -1.802 | 3.11E-02 | 3.46E-02 | 2.27E-02 |
| 64 | P13667     | PDIA4                         | Protein disulfide-isomerase A4                                                    | -1.735            | 70 | 18 | 26 | 114 | 61.4 | 15.8 | 22.8  | -1.735 | -1.174 | -4.346 | 1.64E-07 | 7.79E-05 | 2.52E-12 |
| 65 | Q9NTX5     | ECHDC1                        | Ethylmalonyl-CoA decarboxylase                                                     | -1.671            | 28 | 7  | 1  | 36  | 77.8 | 19.4 | 2.8   | -1.671 | -3.487 | -3.059 | 1.17E-03 | 4.05E-07 | 3.02E-05 |
| 66 | Q7Z4W1     | DCXR                          | L-xylulose reductase                                                               | -1.400            | 23 | 7  | 0  | 30  | 76.7 | 23.3 | 0.0   | -1.400 | -4.065 | -2.788 | 9.91E-03 | 6.51E-07 | 2.11E-04 |
| 67 | Q9Y2Q3     | GSTK1                         | Glutathione S-transferase kappa 1                                                 | -1.383            | 14 | 4  | 3  | 21  | 66.7 | 19.0 | 14.3  | -1.383 | -1.629 | -2.119 | 4.58E-02 | 2.20E-02 | 7.01E-03 |
| 68 | P49748     | ACADVL                        | Very long-chain specific acyl-CoA dehydrogenase, mitochondrial                    | -1.319            | 30 | 10 | 12 | 52  | 57.7 | 19.2 | 23.1  | -1.319 | -1.024 | -3.155 | 4.98E-03 | 2.05E-02 | 1.39E-05 |
| 69 | P42224     | STAT1                         | Signal transducer and activator of transcription 1- alpha/beta                   | -1.309            | 16 | 5  | 0  | 21  | 76.2 | 23.8 | 0.0   | -1.309 | -3.573 | -2.296 | 4.13E-02 | 5.84E-05 | 3.21E-03 |
| 70 | O95994     | AGR2                          | Anterior gradient protein 2 homolog                                                | -1.746            | 58 | 23 | 14 | 95  | 61.1 | 24.2 | 14.7  | -1.746 | -4.079 | 5.21E-04 | 1.57E-06 | 2.65E-10 |
including pancreas, lung, ovary, breast and prostate, frequently suggesting its association with tumor progression and metastasis [13, 14, 26–30]. The HYOU1 protein (hypoxia up-regulated 1, alternatively known as Orp150), belonging to the heat shock protein 70 family, demonstrated its increased expression in prostate, bladder and invasive breast cancer, is suggested to be associated with tumor invasiveness [31].

**Protein-protein network analysis of expressed proteins**

Network analysis of significant proteins is also helpful to understand how they interplay with other key proteins and pathways. In this study the network analysis of protein-protein interaction was performed by utilizing the STRING database version 10 [32, 33]. Therein only experiments, databases and text mining were utilized to avoid less confident predicted interactions. The STRING PPI networks were obtained by applying 70 proteins expressed significantly to LPIA (given in Table 1) and shown in Fig. 2 (also given as Additional file 2: Figure S1). The STRING PPI networks obtained for AIS and MIA are provided as Additional file 3: Figure S2 and Additional file 4: Figure S3. Figure 3 illustrates results of the STRING gene set enrichments (GSes) for LPIA, MIA, and AIS obtained against cancer related KEGG pathways, which were elucidated with their significance rank \( p < 0.05 \) after correction by false discovery rate (FDR). All results are provided in Additional file 1: Table S4. Enrichments on AIS indicated the strong association with pathways of focal adhesion (\( p = 2.69 \times 10^{-16} \)), adherens junction (\( p = 6.45 \times 10^{-12} \)) and leukocyte transendothelial migration (\( p = 9.79 \times 10^{-13} \)). MIA was found to be associated with PI3K-Akt signaling (\( p = 8.25 \times 10^{-6} \)) and predominantly with proteoglycans in cancer (\( p = 3.99 \times 10^{-17} \)). In contrast, LPIA was associated broadly with numerous cancer-related pathways which included proteoglycans in cancer (\( p = 5.94 \times 10^{-17} \)), ErbB signaling (\( p = 2.99 \times 10^{-3} \)), Ras signaling (\( p = 5.77 \times 10^{-3} \)), Rap1 signaling (\( p = 9.72 \times 10^{-3} \)), chemokine signaling (\( p = 7.23 \times 10^{-5} \)), and HIF-1 signaling (\( p = 5.77 \times 10^{-3} \)).

Proteoglycans are known to be important molecular effectors of cell surface and pericellular microenvironments and to have multiple functions in cancer and angiogenesis by interacting with both ligands and receptors that regulate neoplastic growth and neovascularization [34]. Molecules participating in the proteoglycan-related cancer pathway were denoted by red circles in Additional file 3: Figure S2. The ErbB signaling pathway is associated with many cancer pathways. The ErbB family belong epidermal growth factor receptors which play an important role in tumor growth. Over-expression of EGFR occurs around 60 % of non-small cell lung cancer (NSCLC), in which adenocarcinoma has the higher frequency [35]. Hypoxia-inducible factors (HIFs) regulate the transcription of genes that mediate the response to hypoxia (reduced \( O_2 \) availability) [36]. It is considered that diverse products of HIF-1 action such as induction of the Met protein, hepatocyte growth factor (HGF), followed by Met receptor activation may result in the poor prognosis attached to hypoxic tumors, which indeed turn out to be more aggressive that their well-oxygenated counterparts. Molecules participating in the ErbB and HIF-1 signaling pathways were denoted by orange and red circles, respectively, in Fig. 2. Numerous clinical data demonstrated that increased levels of HIF-1 proteins consequenced a poor prognosis and increased patient mortality in many different human cancers including NSCLC [37].

**Conclusion**

Former localized BAC (≤2 cm) lesions have been histologically classified into types A, B and C by Noguchi et al. based on finding of local cancer progression [38]. These lesions, now identified as AIS, MIA or LPIA usually show focal ground-glass opacity (GGO) on chest HRCT (high resolution computed tomography). Generally, AIS shows pure GGO, and representative MIA and LPIA lesions show GGO with some intratumoral areas of collapsed shadow suggesting invasion. There are multiple studies [39, 40] describing that limited lung resection including wedge resection or segmentectomy can cure early adenocarcinomas showing pure GGO. From histologic and radiologic points of view, it is hypothesized that preinvasive AIS progresses to the invasive lesions MIA and LPIA sequentially. Postoperative 5-year recurrence-free survival rates for AIS and MIA are 100 %, while these for LPIA ranged 71.9 to 93.8 % [8–10].

The molecular biological background predisposing the worse prognosis of LPIA compared with AIS and MIA may be in part due to the forms of altered protein expressions found in our present study. Proteins appearing in the step from AIS to MIA are probably important at the initial step of microinvasion. As LPIA prepares characteristics of matured lung cancer, it is reasonable that LPIA expresses a variety of proteins associated with cancer invasion. We believe that some of these proteins are candidates for molecular target therapy to suppress local invasion or distant metastases.

In the new adenocarcinoma subtyping, prognoses of solid or micropapillary predominant invasive adenocarcinomas were reported to be apparently worse than those of other subtypes including lepidic type adenocarcinomas [10, 41, 42]. We imagine that in the future comparative proteomic analyses such as that presented here will contribute to elucidate protein expressions determining malignant grade of various lung adenocarcinoma subtypes, which will further provide important knowledge to understand the carcinogenic process and tumor lineages of lung adenocarcinomas for the benefit of patients with more efficient diagnosis and treatment of these tumors.
Method
Ethics approval
The study protocol conformed to the principles of the Declaration of Helsinki. All patients were provided with informed consent and the study protocol was approved by Tokyo Medical University Hospital institutional ethics committee.

FFPE tissues and sample preparation
Surgically removed lung tissues were fixed with a buffered formalin solution containing 10 – 15-% methanol, and embedded by a conventional method. Archived paraffin blocks of formalin-fixed adenocarcinoma tissues obtained from cases of AIS ($n=3$), MIA ($n=3$), and

Fig. 2 The high-resolution evidence-view of STRING PPI networks obtained on LPIA by using 70 proteins significantly expressed (listed in Table 1), which were generated using default setting in network depth of 50 interactions under medium confidence (0.4) and standard criteria for linkage only with experiments, databases, and textmining.
LPIA ($n = 3$), which were retrieved with the approval from Ethical Committee of Tokyo Medical University Hospital (Acception No. 1964). Patients’ characteristics are listed in Table 2. Paraffin blocks were cut into 4-μm sections for diagnosis and 10-μm sections for proteomics. The 10-μm sections were stained with only haematoxylin. Three pathologists (M.N., Y.K.) independently confirmed adenocarcinoma subtypes using the 4-μm sections stained with haematoxylin-eosin (HE).

**Laser capture and protein solubilization**

Cancerous lesions were identified on serial tissue sections stained with hematoxylin and eosin (HE). For proteomic analysis, a 10-μm thick section prepared from the same tissue block was attached onto DIRECTOR™ slides (Onco-PlexDx, Rockville, MD, USA), de-paraffinized twice with xylene for 5-min, rehydrated with graded ethanol solutions and distilled water, and stained by hematoxylin. Those slides were air-dried and subjected to laser microdissection with a Leica LMD6000 (Leica Micro-systems GmbH, Ernst-Leitz-Strasse, Wetzlar, Germany). At least 30,000 cells ($8.17 \pm 0.03$ mm$^2$) per a tissue were collected directly into a 1.5-mL low-binding plastic tube. From individual three types tissues non-cancerous lesions far from tumors were also collect the same numbers of cells as the pseudo-normal (pN) group ($n = 3$). Representative HE-stained images of adenocarcinoma tissues of AIS, MIA and LPIA were shown in Fig. 4 together with examples of
targeted lesions before and after laser-microdissections (LMD). Proteins were extracted and digested with trypsin using Liquid Tissue™ MS Protein Prep kits (OncoPlexDx, Rockville, MD, USA) according to the manufacturer’s protocol [43].

Exploratory liquid chromatography-tandem mass spectrometry

The digested samples were analyzed in triplicate and in random order by liquid chromatography (LC)-tandem mass spectrometry (MS/MS) using reverse-phase liquid chromatography (RP-LC) interfaced with a LTQ-Orbitrap XL hybrid mass spectrometer (Thermo Fisher Scientific, Bremen, Germany) via a closed nano-electrospray device (ADVANCE Captive Spray Source; AMR Inc. Japan). The RP-LC system consisted of Paradigm MS4 (Michrom Biosources, USA), a peptide Cap-Trap cartridge (0.3 × 5.0 mm) and a capillary separation column (an L-column Micro of 0.1 × 150 mm packed with reverse phase LC-18 gels of 3 μm in diameter and 12-nm pore size, (CERI, Tokyo, Japan)). An autosampler (HTC-PAL, CTC Analytics, Switzerland) loaded an aliquot of samples onto the trap, which then was washed with solvent A (98 % distilled water with 2 % acetonitrile and 0.1 % formic acid) for concentrating peptides on the trap and desalting. Subsequently, the trap was connected in series to the separation column, and the whole columns were developed for 100 min with a linear acetonitrile concentration gradient made from 5 to 35 % solvent B (10 % distilled water and 90 % acetonitrile containing 0.1 % formic acid) at the flow-rate of 300 nL/min.

An LTQ was operated in the data-dependent MS/MS mode to automatically acquire up to three successive MS/MS scans in the centroid mode. The three most intense precursor ions for these MS/MS scans could be selected from a high-resolution MS spectrum (a survey scan) that an Orbitrap previously acquired during a predefined short time window in the profile mode at the resolution of 30,000 and the lock mass of m/z 536.1654 in the m/z range of 350 to 1500. The sets of acquired high-resolution MS and MS/MS spectra for peptides were converted to single data files and they were merged into Mascot generic format files for database searching.

Protein identification

To extract protein candidates characterizing lepidic type adenocarcinoma from the shotgun proteomic datasets experimentally acquired, consisting of 36 runs (triplicate runs of 12 samples from 4 groups, AIS, MIA, LPIA, and pseudo-normal, N), we have utilized a label-free spectral counting approach for proteomic data analysis on protein identification and semi-quantitative comparison.

Semi-quantitative comparison

For calculating spectral counts (SpCs) at the protein level, triplicate X!Tandem [48] results for each patient were simultaneously analyzed with PeptideProphet and the single

| Table 2 Patients’ characteristics | Patient number | Age | Sex | CEA (ng/ml) | Location | Tumor size on CT (mm) | Histological type | TNM classification | EGFR mutation |
|----------------------------------|----------------|-----|-----|-------------|----------|----------------------|------------------|-------------------|---------------|
| 2                                | 55             | M   | 3.9 | Rt.S1       | 11       | pseudo-Normal<sup>a</sup> | AIS              | T1aN0M0           | Unknown       |
| 4                                | 59             | W   | 8.1 | Lt.S1 + 2   | 15       | pseudo-Normal<sup>a</sup> | LPIA             | T1bN0M0          | Unknown       |
| 9                                | 55             | W   | 5.3 | Rt.S4       | 37       | pseudo-Normal<sup>a</sup> | LPIA             | T1bN0M0          | Unknown       |
| 1                                | 63             | W   | 1.9 | Rt.S2       | 15       | Adenocarcinoma        | AIS              | T1aN0M0           | Unknown       |
| 2                                | 55             | M   | 3.9 | Rt.S1       | 11       | Adenocarcinoma        | AIS              | T1aN0M0           | Unknown       |
| 3                                | 56             | W   | 2   | Lt.S8       | 10       | Adenocarcinoma        | AIS              | T1aN0M0           | Unknown       |
| 4                                | 59             | W   | 8.1 | Lt.S3       | 28       | Adenocarcinoma        | AIS              | T1bN0M0          | Unknown       |
| 5                                | 73             | W   | 5.4 | Rt.S5       | 25       | Adenocarcinoma        | AIS              | T1bN0M0          | Unknown       |
| 6                                | 74             | W   | 1.5 | Lt.S3       | 25       | Adenocarcinoma        | AIS              | T1bN0M0          | L858R         |
| 7                                | 78             | W   | 1.5 | Rt.S3       | 37       | Adenocarcinoma        | LPIA             | T2aN0M0          | L858R         |
| 8                                | 72             | W   | 0.6 | Rt.S1       | 51       | Adenocarcinoma        | LPIA             | T2aN0M0          | Unknown       |
| 9                                | 55             | W   | 5.3 | Rt.S4       | 37       | Adenocarcinoma        | LPIA             | T1bN0M0          | Unknown       |

<sup>a</sup>Lesions judged pathologically as non-cancerous regions adjacent to tumors
output file was subjected to ProteinProphet [49]. In addition, all PeptideProphet results were simultaneously analyzed with ProteinProphet. Then, all PeptideProphet and ProteinProphet results were used for extracting significant proteins and computing SpCs with Abacus [20] using the following thresholds: maxiniProb threshold = 0.99 for the minimum PeptideProphet score, and Combined File Prob threshold = 0.9 for the minimum ProteinProphet score in the combined file.

Fold changes of expressed proteins in the base 2 logarithmic scale ($R_{SC}$) were calculated using spectral counting as described [15]. Proteins expressed significantly between two groups were chosen so that their $R_{SC}$ satisfy $>1$ or $<-1$, which correspond to their fold changes $>2$ or $<0.5$, and $p$-value $< 0.05$ in G-test [19]. Although G-test does not require replicates, spectral counts for each protein from triplicates were pooled and used for G-statistic calculation using a two-way contingency table arranged in two rows for a target protein and any other proteins, and two columns for cancer groups on an Excel macro. The Yates correction for continuity was applied to the $2 \times 2$ tables. The correction could enable us to handle the data containing small spectral counts including zero.

Network analysis of protein-protein interactions

Network analysis of protein-protein interactions was carried out by using the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database version 10 [32, 33], in which nodes are proteins and edges are the predicted functional associations based on primary databases comprising of KEGG and GO, and primary literature. STRING can predict these interactions based on neighbourhood, gene fusion products, homology and similarity of coexpression patterning, experiments, databases and textmining. Network interaction scores for each node are expressed as a joint probability derived from curated databases of experimental information, textmining and computationally predicted by genetic proximity [32]. In this study, STRING networks were calculated under the criteria for linkage only with experiments, databases, and textmining with the default settings - medium confidence score: 0.400, network depth: 0 and up to 50 interactions.

Additional files

Additional file 1: Table S1. Proteins characteristic to AIS, which were under $p < 0.05$ (AIS vs LPIA), $R_{SC} > 1$ (LPIA vs AIS), and [AIS] greater than [LPIA] and [MIA].

Additional file 2: Figure S1. The high-resolution evidence-view of STRING PPI networks obtained on LPIA by using 70 proteins significantly expressed (listed in Table 1), which were generated using default setting in network depth of 50 interactions under medium confidence (0.4) and standard criteria for linkage only with experiments, databases, and textmining.

Additional file 3: Figure S2. The high-resolution evidence-view of STRING PPI networks obtained on AIS by using 26 proteins significantly expressed (listed in Table S1), which were generated using default setting in network depth of 50 interactions under medium confidence (0.4) and standard criteria for linkage only with experiments, databases, and textmining.
expressed (listed in Additional file 1: Table S1), which were generated using default setting in network depth of 50 interactions under medium confidence (0.4) and standard criteria for linkage only with experiments, databases, and text mining.

**Additional file 4:** Figure S3. The high-resolution evidence-view of STRING PPI networks obtained on MIA by using 15 proteins significantly expressed (listed in Additional file 1: Table S2), which were generated using default setting in network depth of 50 interactions under medium confidence (0.4) and standard criteria for linkage only with experiments, databases, and text mining.

**Abbreviations**

BAC: Bronchioalveolar carcinoma; AIS: Adenocarcinoma in situ; MIA: Minimally invasive adenocarcinoma; LPIA: Lepidic predominant invasive adenocarcinoma; NSCLC: Non-small cell lung carcinoma; LC: Liquid chromatography; MS: Mass spectrometry; FFPE: Formalin-fixed paraffin embedded; LMD: Laser microdissection; HPLC: High pressure liquid chromatography; MS/MS: Tandem mass spectrometry; SpC: Spectral count; STRING: Search tool for the retrieval of interacting genes/proteins database; KEGG: Kyoto encyclopedia of genes and genomes; GO: Gene ontology; GSE: Gene set enrichment.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

Conceived and designed the experiments: HK MN TN TKO NI TF GMV. Performed the experiments: YK TNA KN. Conceived and designed the experiments: HK MN TN TKO NI TF GMV. Written the paper: YK HK TN KN. All authors read and approved the final manuscript.

**Acknowledgements**

The authors wish to thank all the members of both the Department of Thoracic and Thyroid Surgery, and the Division of Diagnostic Pathology, Tokyo Medical University. This work was supported in part by the research grant support from the Akaeda Medical Research Foundation.

**Author details**

1. Department of Thoracic and Thyroid Surgery, Tokyo Medical University, Tokyo, Japan. 2. Department of Chest Surgery, St. Marianna University School of Medicine, Kanagawa, Japan. 3. Department of Biophysics and Biochemistry, Osaka University Graduate School of Medicine, Suita, Japan. 4. Division of Diagnostic Pathology, Tokyo Medical University Hospital, Tokyo, Japan. 5. Laboratory for Systems Biology and Medicine, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan. 6. Center of Excellence in Biological and Medical Mass Spectrometry, Lund University, BMC, Lund, Sweden. 7. Clinical Protein Science & Imaging, Biomedical Center, Department of Biomedical Engineering, Lund University, BMC, Lund, Sweden. 8. Niizashiki Central General Hospital, Saitama, Japan.

**Received:** 29 January 2015 **Accepted:** 19 June 2015

**Published online:** 03 July 2015

**References**

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics 2008. CA Cancer J Clin. 2008;58:71–90.
2. The database of Japanese Ministry of Health, Labor and Welfare. https://www.mhlw.go.jp/toukei/saikin/hw/jinkou/geppo/nengai09/tekki3.html.
3. The data base of National Cancer Institute at the National Institute of Health, https://www.cancer.gov/cancertopics/types/lung.
4. Nakamura H, Saji H. A worldwide trend of increasing primary adenocarcinoma of the lung. Surg Today. 2011;41:104–12.
5. Koke T, Yamato Y, Asamura H, Tsuchiya R, Sohara Y, Eguchi K, et al. Japanese Joint Committee for Lung Cancer Registration. Improvements in surgical results for lung cancer from 1989 to 1999 in Japan. J Thorac Oncol. 2004;9:1364–9.
6. The National Lung Screening Trial Research Team. Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. N Engl J Med. 2011;365:395–409.
7. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International association for the study of lung cancer/americian thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6(2):1–4.
8. Yoshizawa A, Motoi N, Rely GJ, Sima CS, Gerald WL, Kris MG, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol. 2011;24(3):653–64.
9. Yoshizawa A, Sumiyoshi S, Sonobe M, Kobayashi M, Fujimoto M, Kawakami F, et al. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. J Thoracic Oncol. 2013;8(5):652–61.
10. Gu J, Lu C, Gu J, Chen L, Chu Y, Ji Y, et al. Prognostic significance of the IASLC/ATS/ERS classification in Chinese patients: A single institution retrospective study of 202 lung adenocarcinoma. J Thorac Surg. 2013;107(5):74–80.
11. Fehning TE, Marko-Varga G. Proteomics and disease revisited: the challenge of providing proteomic tools into clinical practice. J Proteome Res. 2010;9:1191–2.
12. Nishimura T, Nomura M, Tojo H, Fuji K, Hamasaki H, Mikami S, et al. Proteomic analysis of laser-microdissected paraffin-embedded tissues: (1) Stage-related protein candidates upon non-metastatic lung adenocarcinoma. J Proteomics. 2010;73:1089–99.
13. Nishimura T, Nomura M, Tojo H, Hamasaki H, Fukuda T, Fuji K, et al. Proteomic analysis of laser-microdissected paraffin-embedded tissues: (2) MRW array for stage-related proteins upon non-metastatic lung adenocarcinoma. J Proteomics. 2010;73:1100–10.
14. Old WM, Meyer-Arendt K, Aveiline-Wolf L, Pierce KG, Mendoza A, Sevinsky JR, et al. Comparison of label-free methods for quantifying human proteins by shotgun proteomics. Mol Cell Proteomics. 2005;4:1487–502.
15. Zybaliow B, Coleman MK, Florens L, Washburn MP. Correlation of relative abundance ratios derived from peptide ion chromatograms and spectrum counting for quantitative proteomic analysis using stable isotope labeling. Anal Chem. 2005;77:6218–24.
16. Fu X, Gharbi SA, Green PS, Atiken ML, Frazer DA, Park DR, et al. Spectral index for assessment of differential protein expression in shotgun proteomics. J Proteome Res. 2008;7(3):845–54.
17. Braisted JC, Kuntumalla S, Vogel C, Marctome EM, Rodrigues AR, Wang R, et al. The APEX Quantitative Proteomics Tool: Generating protein quantitation estimates from LC-MS/MS proteomics results. BMC Bioinformatics. 2008;9:529.
18. McIwen S, Mathews M, Beerman MS, Rubel EW, MacCoss MJ, Noble WS. Estimating relative abundances of proteins from shotgun proteomics data. BMC Bioinformatic. 2012;13:308.
19. Femlin D, Barsur V, Yocum AK, Nesvizhskii AI. Abacus: a computational tool for extracting and pre-processing spectral count data for label-free quantitative proteomic analysis. Proteomics. 2011;11(7):1340–5.
20. Sokal RR, Rohlf FJ. Biometry: the principles and practice of statistics in biological research. New York: W.H. Freeman; 1995. p. 729–31.
21. Zhang S, VerBerkmoes NC, Langston M, Uberbacher E, Hettich RL, Samatova NF. Detecting differential and correlated protein expression in label-free shotgun proteomics. J Proteome Res. 2006;5(1):2909–18.
22. Weaver AM, Cortico tumor inrasiness. Cancer Lett. 2008;265:157–66.
23. Mader CC, Oser M, Magalhaes MA, Bravo-Cordero JJ, Condeelis J, Koleski AJ, et al. An EGFR-Src-Arg-Cortico Pathway Mediates Functional Maturation of Invasodipha and Breast Cancer Cell Invasion. Cancer Res. 2011;71:1730–41.
24. MacGrath SM, Koleski AJ. Cortico in cell migration and cancer at a glance. J Cell Sci. 2012;125:1621–2.
25. Kato H, Nishimura T, Hirano T, Nomura M, Tojo H, Fuji K, et al. A Clinician View and Experience of Proteomic Studies in the Light of Lung Cancer in Japanese Healthcare. J Proteome Res. 2011;10(1):51–7.
26. Norris AM, Gore A, Balboni A, Young A, Longnecker DS, Kroc M. AGR2 is a SMAD4-suppressible gene that modulates MUC1 levels and promotes the initiation and progression of pancreatic intraepithelial neoplasia. Oncogene. 2013;32(33):3867–74.
27. Park K, Chung YJ, So H, Kim K, Park J, Oh M, et al. AGR2, a mucinous ovarian cancer marker, promotes cell proliferation and migration. Exp Mol Med. 2011;43(2):91–100.
29. Salmans ML, Zhao F, Andersen B. The estrogen-regulated anterior gradient 2 (AGR2) protein in breast cancer: a potential drug target and biomarker. Breast Cancer Res. 2013;15(2):204.

30. Ho ME, Quek SI, True LD, Morrissey C, Corey E, Vessella RL, et al. Prostate cancer cell subtypes based on AGR2 and CD10 expression. Mod Pathol. 2013;26(6):849–59.

31. Stojadinovic A, Hooke CD, Nissar N, Kovatch AJ, Kao T-C, et al. HYOU1/Orp150 expression in breast cancer. Med Sci Monit. 2007;13(11):BR231–9.

32. Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2015;43(Database issue):D447–52.

33. STRING: functional protein association networks http://string-db.org/.

34. Iozzo RV, Sanderson RD. Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J. Cell Mol Med. 2011;15(S5):1013–31.

35. Shitov E, Hensing T, Simon GR, Dennis PA, Otterson GA, Bueno R, et al. Molecular pathways and therapeutic targets in lung cancer. Oncotarget. 2014;5(6):1392–433.

36. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene. 2010;29(5):625–34.

37. Swinson DE, Jones JL, Cox G, Richardson D, Harris AL, O’Byrne KJ. Hypoxia-inducible factor-1 alpha in non small cell lung cancer: relation to growth factor, protease and apoptosis pathways. Int J Cancer. 2004;111(4):43–50.

38. Noguchi M, Morikawa A, Kawasaki Y, Yamada T, Hirohashi S, et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer. 1995;75(12):2844–52.

39. Nakamura H, Saji H, Ogata A, Saijo T, Okada S, Kato H. Lung cancer patients showing pure ground-glass opacity on computed tomography are good candidates for wedge resection. Lung Cancer. 2004;44(1):61–8.

40. Nakata M, Sawada S, Yamashita M, Saeki H, Kurita A, Takashima S, et al. Objective radiologic analysis of ground-glass opacity aimed at curative limited resection for small peripheral non-small cell lung cancer. J Thorac Cardiovasc Surg. 2005;129(6):1226–31.

41. Tsuta K, Kawagoe M, Inoue E, Yoshida A, Takahashi F, Sakurai H, et al. The utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations. Lung Cancer. 2013;81(3):371–6.

42. Song Z, Zhu H, Guo Z, Wu W, Sun W, Zhang Y. Prognostic value of the IASLC/ATS/ERS classification in stage I lung adenocarcinoma patients—based on a hospital study in China. Eur J Surg Oncol. 2013;39(11):1262–8.

43. OncoPlexDx Inc. http://www.oncoplexdx.com/.

44. Deutsch EW, Mendoza L, Shetyeberg D, Farrah T, Lam H, Tasman N, et al. A guided tour of the Trans-Proteomic Pipeline. Proteomics. 2010;10(6):1150–9.

45. Pedrioli PG. Trans-proteomic pipeline: a pipeline for proteomic analysis. In: Proteomic Bioinformatics, Methods in Molecular Biology, Vol. 604. New York: Humana Press; 2010. p. 213–38.

46. Imanishi T, Nagai Y, Habara T, Yamasaki C, Takeda J, Mikami S, et al. Full-length transcriptome-based H-invDB throws a new light on chromosome-centric proteomics. J Proteome Res. 2013;12:62–6.

47. Ma K, Vitek O, Nesvizhskii AI. A statistical model-building perspective to identification of MS/MS spectra with PeptideProphet. BMC Bioinformatics. 2012;13 Suppl 16:S1.

48. Searle BC. Scaffold: a bioinformatic tool for validating MS/MS-based proteomic studies. Proteomics. 2010;10(6):1265–9.